Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.33 |
| ▸ | LMNA | P02545 | 4/20 | 0.33 |
| ▸ | HPGD | P15428 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3586940 | 0.79 | GAA (0.39) | SMN1; SMN2ALDH1A1LMNAHPGDMEN1 | |
| SCHEMBL28312825 | 0.76 | LMNA (0.42) | SMN1; SMN2RAB9AALDH1A1LMNAMAPT | |
| SCHEMBL23108224 | 0.75 | MAPK1 (0.34) | ALDH1A1LMNAMAPTTHRBTSHR | |
| SCHEMBL25106572 | 0.75 | SMN1; SMN2 (0.41) | SMN1; SMN2RAB9AALDH1A1LMNAHPGD | |
| SCHEMBL25106764 | 0.75 | SMN1; SMN2 (0.39) | SMN1; SMN2RAB9AALDH1A1LMNAHPGD | |
| SCHEMBL25106758 | 0.73 | SMN1; SMN2 (0.39) | SMN1; SMN2RAB9AALDH1A1LMNAHPGD | |
| SCHEMBL15273680 | 0.72 | HPGD (0.38) | SMN1; SMN2RAB9AALDH1A1LMNAHPGD | |
| SCHEMBL13981849 | 0.67 | ALDH1A1 (0.39) | ALDH1A1LMNAMEN1KMT2ATHRB | |
| SCHEMBL11561448 | 0.67 | ALDH1A1 (0.43) | SMN1; SMN2RAB9AALDH1A1LMNAMAPT | |
| SCHEMBL2515929 | 0.66 | SMN1; SMN2 (0.47) | SMN1; SMN2ALDH1A1LMNAHPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230063457-A1 | DNA-PK INHIBITING COMPOUNDS | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2023-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230063457-A1 | DNA-PK INHIBITING COMPOUNDS | DCK, POLK, ERCC2 | SMN1; SMN2 3212/4885RAB9A 2933/4885ALDH1A1 2447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.